The drug and the program are different questions
Fullness and blood sugar are both affected by a natural gut hormone. Semaglutide acts like that hormone, which is called GLP-1.
U.S. records checked in September 2026 list semaglutide (Ozempic, Wegovy and Rybelsus). Those are brand names. The ingredient name alone does not tell which form is meant.
A program is the service wrapped around that medicine. To compare an offer, write down the product separately from the visits, messages and other services. Then ask which charges belong to each. An attractive name tells little about the contents of the bill.
Put the aim of the visit in plain words. Is it about weight? Is it about blood sugar or another condition a doctor has found? Put that at the top of the question sheet. Use the same aim when asking about the drug and when asking about the bill.
The name on the prescription matters
In the September 2026 records, semaglutide (Ozempic injection) had approved uses tied to diabetes. Semaglutide (Wegovy) had approval for weight care. The shared ingredient did not give them the same approved uses.
The September 2026 records include tablet and injection forms of both Ozempic and Wegovy.
Ask the person writing the prescription to name the exact product in ordinary language. Copy the name into the price request rather than just writing “semaglutide.” Ask the insurer to check that same name and form. Keep the answer beside the planned reason for treatment.
When a pharmacy makes the medicine
A compounded drug is made for a specific need by a pharmacist, doctor or registered drug-making facility.
In the September 2026 rules, a registered facility meant a place that makes batches of sterile medicine and signs up with the Food and Drug Administration (FDA). It did not have to be a pharmacy.
Sterile means free of living germs.
Under the September 2026 rules, FDA registration granted no approval to either the facility or its drugs.
The September 2026 record classed compounded drugs as unapproved by the FDA. They have no agency review of quality or safety before sale, nor a review of whether they work.
In February 2025, the FDA said the nationwide shortage of semaglutide injections was over. A gap in stock at a local pharmacy does not put the drug back on that national list. The list matters because limits on pharmacy-made copies do not apply while a drug is listed as being in shortage.
By the September 2026 review, the shortage no longer provided that exception for semaglutide injections. This did not make all compounding unlawful: a change for a named person could still qualify when the person writing the prescription found that it made a meaningful difference for that person. A lower price alone did not qualify.
Drug review falls within the work of FDA, the Food and Drug Administration. Ask what kind of drug the service has in mind. Does the service mean an approved product, or does it mean a pharmacy-made version? Cost does not settle that point. Keep the answer beside the price where it is easy to see.
Put the next conversation on paper
Bring the planned product name, the advertised terms and the questions that still feel vague. Keep a blank space for what happens after the opening offer. Ask who answers medical questions, who deals with billing and who can explain a prescription claim to the insurer.
There is no need to learn the whole drug vocabulary before asking for a clear answer. A useful answer names the product, describes the care and explains the payment terms. If a reply uses an unfamiliar term, ask for the everyday meaning and the practical effect on the next step.